About the Lab
For more than two decades, the Fagan lab at Washington University in St. Louis (WUSTL) has studied Alzheimer disease (AD) — in particular, characterizing fluid biomarkers of AD, how these biomarkers change throughout the disease course and the utility of these markers in identifying individuals in the preclinical/presymptomatic and early clinical stages of the disease. The lab utilizes enzyme-linked immunosorbent assays (ELISA), bead-based immunoassays, fully-automated assay platforms and ultrasensitive single-molecule counting systems to study protein biomarkers in both cerebrospinal fluid and plasma.
Most of the research in the Fagan lab falls under four categories: 1) comparison of fluid biomarkers with other biomarker modalities and cognitive/clinical measures; 2) fluid biomarker profiles in different AD cohorts; 3) identification of novel fluid biomarkers of AD; and 4) assay development, standardization and validation. For further information on our research, please see our Research Contributions page.
The Fagan lab also functions as a biorepository for multiple studies, including the Memory and Aging Project (MAP, supported by the Knight Alzheimer Disease Research Center [ADRC], the Healthy Aging and Senile Dementia project [HASD], and the Adult Children Study [ACS]), the Dominantly Inherited Alzheimer Network observational study (DIAN), the DIAN Trials Unit (DIAN-TU) and the Alzheimer’s Biomarkers Consortium – Down Syndrome study (ABC-DS). Additionally, the Fagan lab participates in several AD biomarker studies locally (WUSTL), domestically and internationally.